Skip to content

Debt-to-equity at other companies

ALN
Alnylam PharmaceuticalsALNY
0.2×-0.4×
Septerna, Inc. logo
Septerna, Inc.SEPN
0.1×
Regenxbio logo
RegenxbioRGNX
3.4×+3.1×
Gyre Therapeutics, Inc. logo
Gyre Therapeutics, Inc.GYRE
0.0×
Opko Health logo
Opko HealthOPK
0.0×
Ginkgo Bioworks logo
Ginkgo BioworksDNA
0.9×+0.3×

Other financials

Income statement

See full
Operating income-$27.3M-49.2%
Net income-$25.2M-58.7%
EPS (diluted)-$1.34-44.1%

Balance sheet

See full
Cash & equivalents$236.9M-22.8%
Total debt$4.9M+86.1%
Total equity$230.4M-23.5%
Total assets$246.6M-21.7%

Cash flow

See full
Operating cash flow-$18.4M-40.7%
CapEx$19.0K-29.6%
Free cash flow-$18.4M-40.6%

Valuation

See full
Market cap$585.51M+58.3%
Enterprise value$353.51M+438%

Returns & leverage

See full
Return on equity-31.4%
Current ratio18.5×-4.4×

Where this comes from

Calculated from Tectonic Therapeutics’s reported figures.

Based on the most recent quarter.

The official record: Tectonic Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tectonic Therapeutics's debt-to-equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Tectonic Therapeutics's debt-to-equity?
Tectonic Therapeutics (TECX) reported debt-to-equity of 0× in Q1 2026.
How has Tectonic Therapeutics's debt-to-equity changed year-over-year?
Tectonic Therapeutics's debt-to-equity increased by 144.8% year-over-year, from 0× to 0×.
What is the long-term trend for Tectonic Therapeutics's debt-to-equity?
Over 2 years (2021 to 2025), Tectonic Therapeutics's debt-to-equity has grown at a -74.4% compound annual growth rate (CAGR), from 0.1× to 0×.
What does debt-to-equity mean?
Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.